Parsons James T.

Insider Reports History

Location
Minneapolis, MN
Signature
/s/ Scott Kellen, attorney-in-fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Parsons James T.:

Company Role Class Num Shares Value Price $ Report Date Ownership
DiaMedica Therapeutics Inc. Director Common Stock 97,949 $824,730 $8.42 02 Jan 2026 Direct
ONCOLYTICS BIOTECH INC Director Common Shares 31,849 $33,122 $1.04 01 Jan 2026 Direct
DiaMedica Therapeutics Inc. Director Stock Option (right to buy) 0 21 Nov 2025 Direct
Trillium Therapeutics Inc. Chief Financial Officer Stock Option (Right to Buy) 0 17 Nov 2021 Direct

Insider Reports Filed by Parsons James T.

Symbol Company Period Transactions Value $ Form Type Role Filing Time
DMAC DiaMedica Therapeutics Inc. 02 Jan 2026 1 +$85,000 4 Director 06 Jan 2026, 17:24
ONCY ONCOLYTICS BIOTECH INC 01 Jan 2026 0 $0 3 Director 02 Jan 2026, 16:30
DMAC DiaMedica Therapeutics Inc. 21 Nov 2025 2 +$26,400 4 Director 25 Nov 2025, 16:30
DMAC DiaMedica Therapeutics Inc. 01 Jun 2025 1 $0 4 Director 03 Jun 2025, 16:17
DMAC DiaMedica Therapeutics Inc. 02 Jan 2025 2 +$84,997 4 Director 03 Jan 2025, 16:46
DMAC DiaMedica Therapeutics Inc. 01 Jun 2024 1 $0 4 Director 03 Jun 2024, 16:21
DMAC DiaMedica Therapeutics Inc. 02 Jan 2024 1 +$59,998 4 Director 02 Jan 2024, 16:39
DMAC DiaMedica Therapeutics Inc. 01 Jun 2023 1 $0 4 Director 02 Jun 2023, 16:21
DMAC DiaMedica Therapeutics Inc. 01 Jun 2022 1 $0 4 Director 02 Jun 2022, 16:44
DMAC DiaMedica Therapeutics Inc. 03 Jan 2022 1 +$60,047 4 Director 03 Jan 2022, 15:21
/report/000110465921141747-parsons-james-t-2021-11-17 Trillium Therapeutics Inc. 17 Nov 2021 8 $0 4 Chief Financial Officer 19 Nov 2021, 12:29
DMAC DiaMedica Therapeutics Inc. 15 Jul 2021 1 $0 4 Director 16 Jul 2021, 16:45